 |
| |
| |
| |
| |
| |
| |
|
| TissGeneSummary for TAT |
 Gene summary |
| Basic gene information | Gene symbol | TAT |
| Gene name | tyrosine aminotransferase | |
| Synonyms | - | |
| Cytomap | UCSC genome browser: 16q22.1 | |
| Type of gene | protein-coding | |
| RefGenes | NM_000353.2, | |
| Description | L-tyrosine:2-oxoglutarate aminotransferasetyrosine aminotransferase, cytosolic | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 613018 | |
| HGNC : HGNC | ||
| HPRD : 11776 | ||
| Protein | UniProt: go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_TAT | |
| BioGPS: 6898 | ||
| Pathway | NCI Pathway Interaction Database: TAT | |
| KEGG: TAT | ||
| REACTOME: TAT | ||
| Pathway Commons: TAT | ||
| Context | iHOP: TAT | |
| ligand binding site mutation search in PubMed: TAT | ||
| UCL Cancer Institute: TAT | ||
| Assigned class in TissGDB* | A | |
| Included tissue-specific gene expression resources | HPA,TiGER,GTEx | |
| Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Liver | |
| Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | LIHC | |
| Reference showing the relevant tissue of TAT | Two liver-enriched trans-acting factors support the tissue-specific basal transcription from the rat tyrosine aminotransferase promoter. J Steroid Biochem Mol Biol. 1992 Mar;41(3-8):747-52. (pmid:1348627) go to article | |
| Description by TissGene annotations | Significant down-regulated DEG TissgsKTS CNV lost TissGeneKTS Fused withTSGene | |
| * Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO term | PubMed ID | GO:0006103 | 2-oxoglutarate metabolic process | 7999802 | GO:0006536 | glutamate metabolic process | 7999802 | GO:0006572 | tyrosine catabolic process | 7999802 | GO:0006103 | 2-oxoglutarate metabolic process | 7999802 | GO:0006536 | glutamate metabolic process | 7999802 | GO:0006572 | tyrosine catabolic process | 7999802 |
| Top |
| TissGeneExp for TAT |
| Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
 |
| Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
 |
| Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| - Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
| Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
| COAD | -2.606275437 | 0.656128409 | -3.262403846 | 4.86E-11 | 7.55E-10 |
| BRCA | 1.37061822 | 5.752488396 | -4.381870175 | 8.27E-16 | 4.55E-15 |
| KICH | -2.971137745 | -1.654869745 | -1.316268 | 6.42E-07 | 2.49E-06 |
| LIHC | 9.066938255 | 11.90820826 | -2.84127 | 1.59E-07 | 1.06E-06 |
| Top |
| TissGene-miRNA for TAT |
| Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
| Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
| Top |
| TissGeneMut for TAT |
| TissGeneSNV for TAT |
| nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
 |
 |
| Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
 |
| - nsSNVs sorted by frequency. |
| AAchange | Cancer type | # samples |
| p.R367H | GBM | 2 |
| p.A430V | COAD | 2 |
| p.E207K | SKCM | 2 |
| p.S193C | BLCA | 1 |
| p.E385K | READ | 1 |
| p.H229Y | BLCA | 1 |
| p.G290C | LUAD | 1 |
| p.V20M | BRCA | 1 |
| p.W194L | CESC | 1 |
| p.A58P | CESC | 1 |
| p.R37K | SKCM | 1 |
| p.W194* | SKCM | 1 |
| p.E182G | UCEC | 1 |
| p.G180R | SKCM | 1 |
| p.N54S | SKCM | 1 |
| p.E92K | SKCM | 1 |
| p.S103L | SKCM | 1 |
| p.R333C | SKCM | 1 |
| p.P67Q | LUAD | 1 |
| p.E248D | CESC | 1 |
| p.A359D | ESCA | 1 |
| p.E92D | UCEC | 1 |
| p.L346R | OV | 1 |
| p.R27K | LUAD | 1 |
| p.V419I | UCEC | 1 |
| p.A430V | STAD | 1 |
| p.G325R | SKCM | 1 |
| p.R333H | UCEC | 1 |
| p.L343V | SKCM | 1 |
| p.S77F | SKCM | 1 |
| p.P423L | SKCM | 1 |
| p.M5I | SKCM | 1 |
| p.G32R | SKCM | 1 |
| p.A407T | KICH | 1 |
| p.P158R | LUAD | 1 |
| p.Y4H | STAD | 1 |
| p.R333L | LUAD | 1 |
| p.S29F | SKCM | 1 |
| p.A39D | STAD | 1 |
| p.M97I | HNSC | 1 |
| p.S369P | THYM | 1 |
| p.C409F | LIHC | 1 |
| p.S112Y | LUSC | 1 |
| p.D269N | UCEC | 1 |
| p.G325E | SKCM | 1 |
| p.R315S | LUAD | 1 |
| p.R119Q | KIRP | 1 |
| p.R281C | LUAD | 1 |
| p.R281C | UCEC | 1 |
| p.R281L | LUAD | 1 |
| p.E424* | ESCA | 1 |
| p.T393M | DLBC | 1 |
| p.A100V | STAD | 1 |
| p.E424X | ESCA | 1 |
| p.E337Q | BLCA | 1 |
| p.R306Q | UCEC | 1 |
| p.P15S | COAD | 1 |
| p.W291* | SKCM | 1 |
| p.E304K | SKCM | 1 |
| p.Y260C | LIHC | 1 |
| p.I244M | HNSC | 1 |
| p.E304K | PAAD | 1 |
| p.G180E | SKCM | 1 |
| p.D80N | READ | 1 |
| p.R306* | BLCA | 1 |
| p.S256L | SKCM | 1 |
| p.N13K | LUAD | 1 |
| p.T321I | SKCM | 1 |
| p.A49T | COAD | 1 |
| p.D61N | SKCM | 1 |
| p.K208T | STAD | 1 |
| p.S16L | SKCM | 1 |
| p.M97I | SKCM | 1 |
| p.E191D | UCEC | 1 |
| p.D453N | SKCM | 1 |
| p.Q449L | SKCM | 1 |
| p.R57Q | KIRC | 1 |
| p.E195K | STAD | 1 |
| p.P3S | OV | 1 |
| p.R433Q | SKCM | 1 |
| p.E411G | LGG | 1 |
| Top |
| TissGeneCNV for TAT |
| Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
 |
| Top |
| TissGeneFusions for TAT |
| Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
| Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
| Chimerdb3.0 | ChiTaRs | NA | BG562569 | TAT-PPP2R1B | chr16:71601625 | chr11:111610550 | |
| TCGAfusionPortal | PRADA | LGG | TCGA-HT-7857-01A | MAP9-TAT | CDS-5UTR | Chr4:156281320 | Chr16:71610330 |
| Top |
| TissGeneNet for TAT |
| Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
| BRCA (tumor) | BRCA (normal) |
| TAT, HNF4A, ONECUT1, SETDB1, CDK9, SMARCA2, SUV39H1, SETDB2, EHMT2, NCOA2, SMARCB1, EP300, SMARCC2, CCNT1, SETMAR, GRN, SMARCC1, MDFIC (tumor) | TAT, HNF4A, ONECUT1, SETDB1, CDK9, SMARCA2, SUV39H1, SETDB2, EHMT2, NCOA2, SMARCB1, EP300, SMARCC2, CCNT1, SETMAR, GRN, SMARCC1, MDFIC (normal) |
 |  |
| COAD (tumor) | COAD (normal) |
| TAT, HNF4A, ONECUT1, SETDB1, CDK9, SMARCA2, SUV39H1, SETDB2, EHMT2, NCOA2, SMARCB1, EP300, SMARCC2, CCNT1, SETMAR, GRN, SMARCC1, MDFIC (tumor) | TAT, HNF4A, ONECUT1, SETDB1, CDK9, SMARCA2, SUV39H1, SETDB2, EHMT2, NCOA2, SMARCB1, EP300, SMARCC2, CCNT1, SETMAR, GRN, SMARCC1, MDFIC (normal) |
 |  |
| HNSC (tumor) | HNSC (normal) |
| TAT, HNF4A, ONECUT1, SETDB1, CDK9, SMARCA2, SUV39H1, SETDB2, EHMT2, NCOA2, SMARCB1, EP300, SMARCC2, CCNT1, SETMAR, GRN, SMARCC1, MDFIC (tumor) | TAT, HNF4A, ONECUT1, SETDB1, CDK9, SMARCA2, SUV39H1, SETDB2, EHMT2, NCOA2, SMARCB1, EP300, SMARCC2, CCNT1, SETMAR, GRN, SMARCC1, MDFIC (normal) |
 |  |
| KICH (tumor) | KICH (normal) |
| TAT, HNF4A, ONECUT1, SETDB1, CDK9, SMARCA2, SUV39H1, SETDB2, EHMT2, NCOA2, SMARCB1, EP300, SMARCC2, CCNT1, SETMAR, GRN, SMARCC1, MDFIC (tumor) | TAT, HNF4A, ONECUT1, SETDB1, CDK9, SMARCA2, SUV39H1, SETDB2, EHMT2, NCOA2, SMARCB1, EP300, SMARCC2, CCNT1, SETMAR, GRN, SMARCC1, MDFIC (normal) |
 |  |
| KIRC (tumor) | KIRC (normal) |
| TAT, HNF4A, ONECUT1, SETDB1, CDK9, SMARCA2, SUV39H1, SETDB2, EHMT2, NCOA2, SMARCB1, EP300, SMARCC2, CCNT1, SETMAR, GRN, SMARCC1, MDFIC (tumor) | TAT, HNF4A, ONECUT1, SETDB1, CDK9, SMARCA2, SUV39H1, SETDB2, EHMT2, NCOA2, SMARCB1, EP300, SMARCC2, CCNT1, SETMAR, GRN, SMARCC1, MDFIC (normal) |
 |  |
| KIRP (tumor) | KIRP (normal) |
| TAT, HNF4A, ONECUT1, SETDB1, CDK9, SMARCA2, SUV39H1, SETDB2, EHMT2, NCOA2, SMARCB1, EP300, SMARCC2, CCNT1, SETMAR, GRN, SMARCC1, MDFIC (tumor) | TAT, HNF4A, ONECUT1, SETDB1, CDK9, SMARCA2, SUV39H1, SETDB2, EHMT2, NCOA2, SMARCB1, EP300, SMARCC2, CCNT1, SETMAR, GRN, SMARCC1, MDFIC (normal) |
 |  |
| LIHC (tumor) | LIHC (normal) |
| TAT, HNF4A, ONECUT1, SETDB1, CDK9, SMARCA2, SUV39H1, SETDB2, EHMT2, NCOA2, SMARCB1, EP300, SMARCC2, CCNT1, SETMAR, GRN, SMARCC1, MDFIC (tumor) | TAT, HNF4A, ONECUT1, SETDB1, CDK9, SMARCA2, SUV39H1, SETDB2, EHMT2, NCOA2, SMARCB1, EP300, SMARCC2, CCNT1, SETMAR, GRN, SMARCC1, MDFIC (normal) |
 |  |
| LUAD (tumor) | LUAD (normal) |
| TAT, HNF4A, ONECUT1, SETDB1, CDK9, SMARCA2, SUV39H1, SETDB2, EHMT2, NCOA2, SMARCB1, EP300, SMARCC2, CCNT1, SETMAR, GRN, SMARCC1, MDFIC (tumor) | TAT, HNF4A, ONECUT1, SETDB1, CDK9, SMARCA2, SUV39H1, SETDB2, EHMT2, NCOA2, SMARCB1, EP300, SMARCC2, CCNT1, SETMAR, GRN, SMARCC1, MDFIC (normal) |
 |  |
| LUSC (tumor) | LUSC (normal) |
| TAT, HNF4A, ONECUT1, SETDB1, CDK9, SMARCA2, SUV39H1, SETDB2, EHMT2, NCOA2, SMARCB1, EP300, SMARCC2, CCNT1, SETMAR, GRN, SMARCC1, MDFIC (tumor) | TAT, HNF4A, ONECUT1, SETDB1, CDK9, SMARCA2, SUV39H1, SETDB2, EHMT2, NCOA2, SMARCB1, EP300, SMARCC2, CCNT1, SETMAR, GRN, SMARCC1, MDFIC (normal) |
 |  |
| PRAD (tumor) | PRAD (normal) |
| TAT, HNF4A, ONECUT1, SETDB1, CDK9, SMARCA2, SUV39H1, SETDB2, EHMT2, NCOA2, SMARCB1, EP300, SMARCC2, CCNT1, SETMAR, GRN, SMARCC1, MDFIC (tumor) | TAT, HNF4A, ONECUT1, SETDB1, CDK9, SMARCA2, SUV39H1, SETDB2, EHMT2, NCOA2, SMARCB1, EP300, SMARCC2, CCNT1, SETMAR, GRN, SMARCC1, MDFIC (normal) |
 |  |
| STAD (tumor) | STAD (normal) |
| TAT, HNF4A, ONECUT1, SETDB1, CDK9, SMARCA2, SUV39H1, SETDB2, EHMT2, NCOA2, SMARCB1, EP300, SMARCC2, CCNT1, SETMAR, GRN, SMARCC1, MDFIC (tumor) | TAT, HNF4A, ONECUT1, SETDB1, CDK9, SMARCA2, SUV39H1, SETDB2, EHMT2, NCOA2, SMARCB1, EP300, SMARCC2, CCNT1, SETMAR, GRN, SMARCC1, MDFIC (normal) |
 |  |
| THCA (tumor) | THCA (normal) |
| TAT, HNF4A, ONECUT1, SETDB1, CDK9, SMARCA2, SUV39H1, SETDB2, EHMT2, NCOA2, SMARCB1, EP300, SMARCC2, CCNT1, SETMAR, GRN, SMARCC1, MDFIC (tumor) | TAT, HNF4A, ONECUT1, SETDB1, CDK9, SMARCA2, SUV39H1, SETDB2, EHMT2, NCOA2, SMARCB1, EP300, SMARCC2, CCNT1, SETMAR, GRN, SMARCC1, MDFIC (normal) |
 |  |
| Top |
| TissGeneProg for TAT |
| Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
 |
| Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Top |
| TissGeneClin for TAT |
| TissGeneDrug for TAT |
| Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
| DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| DB00135 | L-Tyrosine | Small molecule | Approved|Nutraceutical |
| Top |
| TissGeneDisease for TAT |
| Disease information associated with TissGene (DisGeNet, 2016-06-01) |
| Disease ID | Disease name | # pubmeds | Source |
| umls:C0019693 | HIV Infections | 209 | BeFree |
| umls:C0268487 | Tyrosine Transaminase Deficiency Disease | 11 | BeFree,CLINVAR,ORPHANET,UNIPROT |
| umls:C1518296 | Neuropathogenesis | 7 | BeFree |
| umls:C0162872 | Aortic Aneurysm, Thoracic | 6 | BeFree |
| umls:C0001175 | Acquired Immunodeficiency Syndrome | 5 | BeFree |
| umls:C0023418 | leukemia | 5 | BeFree |
| umls:C0019348 | Herpes Simplex Infections | 4 | BeFree |
| umls:C0268483 | Tyrosinemias | 4 | BeFree,CTD_human |
| umls:C0006142 | Malignant neoplasm of breast | 3 | BeFree |
| umls:C0023524 | Leukoencephalopathy, Progressive Multifocal | 3 | BeFree |
| umls:C0027627 | Neoplasm Metastasis | 3 | BeFree |
| umls:C0079731 | B-Cell Lymphomas | 3 | BeFree |
| umls:C0678222 | Breast Carcinoma | 3 | BeFree |
| umls:C1519680 | Tumor Immunity | 3 | BeFree |
| umls:C2239176 | Liver carcinoma | 3 | BeFree |
| umls:C0002736 | Amyotrophic Lateral Sclerosis | 2 | BeFree |
| umls:C0004114 | Astrocytoma | 2 | BeFree |
| umls:C0011570 | Mental Depression | 2 | BeFree |
| umls:C0011581 | Depressive disorder | 2 | BeFree |
| umls:C0013146 | Drug abuse | 2 | BeFree |
| umls:C0020429 | Hyperalgesia | 2 | BeFree |
| umls:C0023449 | Acute lymphocytic leukemia | 2 | BeFree |
| umls:C0025286 | Meningioma | 2 | BeFree |
| umls:C0025362 | Mental Retardation | 2 | BeFree |
| umls:C0029925 | Ovarian Carcinoma | 2 | BeFree |
| umls:C0280100 | Solid tumour | 2 | BeFree |
| umls:C0524851 | Neurodegenerative Disorders | 2 | BeFree |
| umls:C0699790 | Colon Carcinoma | 2 | BeFree |
| umls:C0870082 | Hyperkeratosis | 2 | BeFree |
| umls:C1762616 | Meningioma, benign, no ICD-O subtype | 2 | BeFree |
| umls:C1961102 | Precursor Cell Lymphoblastic Leukemia Lymphoma | 2 | BeFree |
| umls:C0003864 | Arthritis | 1 | BeFree |
| umls:C0003873 | Rheumatoid Arthritis | 1 | BeFree |
| umls:C0007131 | Non-Small Cell Lung Carcinoma | 1 | BeFree |
| umls:C0007134 | Renal Cell Carcinoma | 1 | BeFree |
| umls:C0007222 | Cardiovascular Diseases | 1 | BeFree |
| umls:C0007785 | Cerebral Infarction | 1 | BeFree |
| umls:C0010692 | Cystitis | 1 | BeFree |
| umls:C0011860 | Diabetes Mellitus, Non-Insulin-Dependent | 1 | BeFree |
| umls:C0012739 | Disseminated Intravascular Coagulation | 1 | BeFree |
| umls:C0014057 | Japanese Encephalitis | 1 | BeFree |
| umls:C0017636 | Glioblastoma | 1 | BeFree |
| umls:C0017638 | Glioma | 1 | BeFree |
| umls:C0021051 | Immunologic Deficiency Syndromes | 1 | BeFree |
| umls:C0021367 | Mammary Ductal Carcinoma | 1 | BeFree |
| umls:C0022116 | Ischemia | 1 | BeFree |
| umls:C0022568 | Keratitis | 1 | BeFree |
| umls:C0023467 | Leukemia, Myelocytic, Acute | 1 | BeFree |
| umls:C0023976 | Long QT Syndrome | 1 | BeFree |
| umls:C0024299 | Lymphoma | 1 | BeFree |
| umls:C0024312 | Lymphopenia | 1 | BeFree |
| umls:C0025268 | Multiple Endocrine Neoplasia Type 2a | 1 | BeFree |
| umls:C0027796 | Neuralgia | 1 | BeFree |
| umls:C0027819 | Neuroblastoma | 1 | BeFree |
| umls:C0030193 | Pain | 1 | BeFree |
| umls:C0033860 | Psoriasis | 1 | BeFree |
| umls:C0036220 | Kaposi Sarcoma | 1 | BeFree |
| umls:C0036690 | Septicemia | 1 | BeFree |
| umls:C0039614 | Tetanus | 1 | BeFree |
| umls:C0078911 | AIDS-Associated Nephropathy | 1 | BeFree |
| umls:C0206754 | Neuroendocrine Tumors | 1 | BeFree |
| umls:C0235782 | Gallbladder Carcinoma | 1 | BeFree |
| umls:C0235974 | Pancreatic carcinoma | 1 | BeFree |
| umls:C0242379 | Malignant neoplasm of lung | 1 | BeFree |
| umls:C0243026 | Sepsis | 1 | BeFree |
| umls:C0263641 | Epithelial hyperplasia of skin | 1 | BeFree |
| umls:C0266929 | Chronic Periodontitis | 1 | BeFree |
| umls:C0268125 | Purine-nucleoside phosphorylase deficiency | 1 | BeFree |
| umls:C0271650 | Impaired glucose tolerance | 1 | BeFree |
| umls:C0272375 | Antithrombin III Deficiency | 1 | BeFree |
| umls:C0275522 | Asymptomatic Infections | 1 | BeFree |
| umls:C0278488 | Carcinoma breast stage IV | 1 | BeFree |
| umls:C0281361 | Adenocarcinoma of pancreas | 1 | BeFree |
| umls:C0282607 | Vascular Neoplasms | 1 | BeFree |
| umls:C0338656 | Impaired cognition | 1 | BeFree |
| umls:C0344307 | Absence of pain sensation | 1 | BeFree |
| umls:C0346647 | Malignant neoplasm of pancreas | 1 | BeFree |
| umls:C0376358 | Malignant neoplasm of prostate | 1 | BeFree |
| umls:C0525041 | Neurobehavioral Manifestations | 1 | BeFree |
| umls:C0553681 | Hypofibrinogenemia | 1 | BeFree |
| umls:C0596263 | Carcinogenesis | 1 | BeFree |
| umls:C0600139 | Prostate carcinoma | 1 | BeFree |
| umls:C0677886 | Epithelial ovarian cancer | 1 | BeFree |
| umls:C0684249 | Carcinoma of lung | 1 | BeFree |
| umls:C0700095 | Central neuroblastoma | 1 | BeFree |
| umls:C0751214 | Hyperalgesia, Thermal | 1 | BeFree |
| umls:C0917798 | Cerebral Ischemia | 1 | BeFree |
| umls:C1458155 | Mammary Neoplasms | 1 | BeFree |
| umls:C1516170 | Cancer Cell Growth | 1 | BeFree |
| umls:C1519670 | Tumor Angiogenesis | 1 | BeFree |
| umls:C1527349 | Ductal Breast Carcinoma | 1 | BeFree |
| umls:C1842981 | NEUROTICISM | 1 | BeFree |
| umls:C1879362 | Hypertyrosinemia | 1 | BeFree |
| umls:C2717961 | Thrombotic Microangiopathies | 1 | BeFree |
| umls:C2745900 | Promyelocytic leukemia | 1 | BeFree |
Copyright 2016-Present - The University of Texas Health Science Center at Houston (UTHealth) Web File Viewing | How to Report, Fraud, Waste and Abuse | State of Texas | Statewide Search | Texas Homeland Security | Site Policies |